Recent developments reflect Mainz Biomed's strategic realignment, capital raising efforts, and clinical progress in pancreatic cancer detection.

• Mainz Biomed announced plans to present its flagship ColoAlert product at MEDICA 2025, a major medical trade fair [N1].
• The company partnered with CARE Diagnostica to enhance colorectal cancer screening in Germany, supporting market presence in Europe [N2].
• Key achievements and corporate updates for the first half of 2025 were announced, highlighting clinical and operational progress [N3].
• Mainz Biomed secured public funding from ISB for its pancreatic cancer early detection project, supporting PancAlert development [N4].
• Feasibility studies for the PancAlert blood test and non-invasive pancreatic cancer screening test were initiated in June 2025 [N5][N6].
• The company announced pricing of a $4 million follow-on offering and warrant amendments to fund operations [N7].
• Plans for an interim readout of the EAArly DETECT 2 colorectal cancer study were disclosed, indicating ongoing clinical validation efforts [N8].

Mainz Biomed has developed advanced genetic diagnostic tests with strong clinical validation for colorectal and pancreatic cancer detection, including exclusive rights to novel mRNA biomarkers and AI algorithms. The company's PancAlert pancreatic cancer screening test is supported by government grants and feasibility studies, representing a potential innovative product in a high-need area. The strategic pivot to focus on pancreatic cancer detection and post-quantum cybersecurity may open new growth avenues. Recent capital raises and board appointments align with this strategy, potentially enabling operational execution and product commercialization.

The company faces significant financial challenges, including a net loss of $16.2 million in 2025 and liquidity ratios below 1, indicating potential funding constraints. The decision to wind down ColoAlert and next-generation colorectal cancer products and sell related intellectual property may disrupt revenue streams and market presence. The strategic shift to post-quantum cybersecurity represents a departure from its core diagnostic business, introducing execution risk and uncertainty. Regulatory compliance costs have increased following the loss of foreign private issuer status. Nasdaq minimum bid price deficiency poses a risk to listing status.

Mainz Biomed's moat is based on proprietary genetic diagnostic technologies integrating validated biomarkers with advanced PCR and AI-driven algorithms for early cancer detection. The company holds exclusive licenses for novel mRNA biomarkers and AI algorithms for pancreatic cancer detection, supported by clinical validation studies demonstrating high sensitivity and specificity. Its ColoAlert product had CE-IVD certification and demonstrated strong clinical performance in European and US studies. Manufacturing capabilities in Mainz, Germany, and partnerships such as with CARE Diagnostica enhance its market presence. However, the recent strategic pivot and sale of ColoAlert IP reduce near-term product continuity, and the company faces liquidity constraints, which may impact its competitive positioning.

• Liquidity and Funding Risk: The company reported a current ratio of 0.5 and cash ratio of 0.52 as of December 31, 2025, indicating limited liquidity to cover short-term obligations. Continued net losses and cash burn may require additional financing.
• Strategic Pivot Execution Risk: The shift from colorectal cancer diagnostics to pancreatic cancer detection and post-quantum cybersecurity involves significant operational changes, potential dilution of focus, and execution challenges.
• Regulatory and Compliance Risk: Loss of foreign private issuer status increases regulatory and compliance costs under U.S. securities laws, potentially impacting financial resources.
• Market and Competitive Risk: The sale of ColoAlert intellectual property and discontinuation of next-generation colorectal cancer products may reduce competitive positioning and revenue opportunities in established markets.
• Listing Compliance Risk: The company received a Nasdaq minimum bid price deficiency notice with a compliance deadline in September 2026, risking potential delisting if not resolved.

• Mainz Biomed N.V. is a public company incorporated under Dutch law, headquartered in Mainz, Germany, with approximately 10 full-time and 3 part-time employees as of March 30, 2026 [S1].
• Historically, Mainz Biomed developed and sold in-vitro diagnostic (IVD) tests for early cancer detection, including the ColoAlert colorectal cancer screening test marketed in Europe [S1].
• In 2025, the company acquired an exclusive license from Liquid Bioscience, Inc. for novel mRNA biomarkers and a proprietary AI algorithm for non-invasive pancreatic cancer detection via blood test, with an option to acquire exclusive global rights [S1].
• Mainz Biomed is developing PancAlert, a stool-based screening test for pancreatic cancer, supported by non-refundable government grants [S1].
• In February 2026, the company decided to wind down ColoAlert and next-generation colorectal cancer screening product development, selling ColoAlert intellectual property in March 2026 and marketing the next-generation IP for sale [S1].
• The company is realigning its strategy to focus on post-quantum cybersecurity business expansion while continuing pancreatic cancer test commercialization, including a planned name change to Quantum Cyber N.V. and ticker change to QUCY [S1].
• ColoAlert was a CE-IVD certified multitarget stool test combining fecal immunochemical test (FIT) and PCR analysis of tumor DNA markers, with clinical studies showing high sensitivity and specificity for colorectal cancer and advanced adenomas [S1].
• The company conducted multiple clinical studies (ColoFuture, eAArly DETECT, and pooled analyses) demonstrating high sensitivity and specificity of its mRNA-based colorectal cancer screening tests in Europe and the US [S1].
• Mainz Biomed initiated feasibility studies for PancAlert blood and stool tests for pancreatic cancer detection in 2025 [N4][N5][N6][S1].
• The company has received public funding for pancreatic cancer early detection projects [N4].
• Recent corporate developments include a $6 million private placement in two tranches to fund operations [N7].
• The company announced plans to present ColoAlert at MEDICA 2025, a major medical trade fair [N1].
• Mainz Biomed partnered with CARE Diagnostica to enhance colorectal cancer screening in Germany [N2].
• Financial snapshot as of December 31, 2025: cash and equivalents of $1.91 million (as of June 30, 2025), current assets of $1.84 million, current liabilities of $3.69 million, resulting in a current ratio of 0.5 and cash ratio of 0.52 [S1].
• The company reported a net loss of $16.2 million and basic and diluted EPS of -$2.7 for fiscal year 2025 [S1].
• The company has implemented cost reduction measures including a 65% reduction in personnel and closure or sale of its European Oncology Lab [S1].
• The company ceased to qualify as a foreign private issuer as of January 1, 2026, and now reports as a domestic issuer under U.S. securities laws [S1].
• The company faces Nasdaq minimum bid price deficiency notification with a compliance period until September 16, 2026 [S1].
• Significant equity transactions include a securities purchase agreement with David E. Lazar involving convertible preferred shares and board appointments to align with new strategic focus [S1].